De Mattos-Arruda, Leticia http://orcid.org/0000-0002-4992-3645
Cortes, Javier http://orcid.org/0000-0001-7623-1583
Blanco-Heredia, Juan
Tiezzi, Daniel G. http://orcid.org/0000-0002-2660-0093
Villacampa, Guillermo
Gonçalves-Ribeiro, Samuel http://orcid.org/0000-0002-0261-3965
Paré, Laia
Souza, Carla Anjos
Ortega, Vanesa
Sammut, Stephen-John
Cusco, Pol
Fasani, Roberta
Chin, Suet-Feung http://orcid.org/0000-0001-5697-1082
Perez-Garcia, Jose
Dienstmann, Rodrigo
Nuciforo, Paolo
Villagrasa, Patricia
Rubio, Isabel T.
Prat, Aleix http://orcid.org/0000-0003-2377-540X
Caldas, Carlos http://orcid.org/0000-0003-3547-1489
Article History
Received: 24 September 2020
Accepted: 3 May 2021
First Online: 7 June 2021
Competing interests
: L.D.M.A. has received honoraria for participation in a speaker’s bureau/consultancy from Roche, and reports research collaboration and support from NanoString Technologies. J.C. reports consulting from Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Honoraria: Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme, Daiichi Sankyo. Research funding to the Institution: Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C., Queen Mary University of London. Stock, patents and intellectual property: MedSIR. Travel, accommodation, expenses: Roche, Novartis, Eisai, pfizer, Daiichi Sankyo. A.P. reports consulting fees from Nanostring Technologies Roche, Pfizer, Novartis and Daiichi Sankyo outside the submitted work. C.C. is a member of the AstraZeneca External Science Panel and has research grants from Roche, Genentech, AstraZeneca, and Servier that are administered by the University of Cambridge. The remaining authors declare no competing interests.